throbber
Page 1 of 6
`
`Allergan Introduces RESTASIS
`MULTIDOSE™ (Cyclosporine
`Ophthalmic Emulsion) 0.05%, a New
`Delivery System for the One and Only
`FDA Approved Treatment to Help
`Patients Produce More of Their Own
`Tears
`RESTASIS® has Been Prescribed for 6.4 Million Patients Since its Launch
`and is Now Available in a Preservative Free, Multi-Dose Bottle
`
`NEWS PROVIDED BY
`Allergan plc
`○
`28 Oct, 2016, 09:47 ET
`
`DUBLIN, Oct. 28, 2016 /PRNewswire/ -- Allergan plc (NYSE:  AGN) announced today
`that it has received approval from the U.S. Food and Drug Administration (FDA) for
`RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%, a
`preservative-free, multi-dose bottle offering the same preservative-free formulation
`
`http://www.prnewswire.com/news-releases/allergan-introduces-restasis-multidose-cyclosporine-ophthalmic-emulsion-005-a-new-delivery-system-for-the-one-and-only-fda-app...
`
`MYLAN - EXHIBIT 1066
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`

`

`Page 2 of 6
`
`of RESTASIS since the launch in 2003. RESTASIS® is the one and only prescription
`treatment FDA approved to help patients with a type of Chronic Dry Eye make
`more of their own tears.
`
`Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
`
`RESTASIS® helps increase your eyes' natural ability to produce tears, which may be
`reduced by inflammation due to Chronic Dry Eye. RESTASIS® did not increase tear
`production in patients using anti-inflammatory eye drops or tear duct plugs.
`
`"RESTASIS MULTIDOSE™ will be an important addition to the Allergan family of
`dry eye products, as it will enable healthcare providers to offer an additional option
`for those patients who may prefer their eye drops in a multi-dose bottle versus
`single-use vials," said Neda Shamie, MD, fellowship-trained cornea  and cataract
`specialist, of Advanced Vision Care, of Los Angeles, Calif.
`
`RESTASIS MULTIDOSE™ is designed with a patented unidirectional valve and air
`filter technology that eliminates the need for a preservative. The new multi-dose
`bottle uses less plastic than a package of single-use vials and will be available for
`the same price.  
`
`"RESTASIS MULTIDOSE™ exemplifies Allergan's commitment to innovation and
`customer responsiveness," said David Nicholson, Chief R&D Officer at Allergan. 
`"Through our Open Science model, we drive to deliver advancements in highly
`engineered developments, such as the new multi-dose bottle."
`
`About Chronic Dry Eye
`
`http://www.prnewswire.com/news-releases/allergan-introduces-restasis-multidose-cyclosporine-ophthalmic-emulsion-005-a-new-delivery-system-for-the-one-and-only-fda-app...
`
`

`

`Page 3 of 6
`
`One type of chronic dry eye is caused by reduced tear production due to
`inflammation. Dry eye is often a chronic disease that can be caused by advanced
`age, contact lens wear, certain medications, eye diseases, other medical conditions
`or environmental factors. Without enough tears, the film protecting the eye can
`break down, creating dry spots on the cornea.
`
`About RESTASIS
`
`RESTASIS® and RESTASIS MULTIDOSE Ophthalmic Emulsion help increase your
`TM
`eyes' natural ability to produce tears, which may be reduced by inflammation due
`to Chronic Dry Eye. RESTASIS® and RESTASIS MULTIDOSE did not increase tear
`TM
`production in patients using anti-inflammatory eye drops or tear duct plugs. 
`
`Important Safety Information
`Do not use RESTASIS® and RESTASIS MULTIDOSE Ophthalmic Emulsion if you
`TM
`are allergic to any of the ingredients.  Be careful not to touch the container tip to
`your eye or other surfaces, to help avoid eye injury and contamination.  RESTASIS®
`and RESTASIS MULTIDOSE should not be used while wearing contact lenses. If
`TM
`contact lenses are worn, they should be removed prior to use of RESTASIS® and
`RESTASIS MULTIDOSE and may be reinserted after 15 minutes.  
`TM
`
`The most common side effect is a temporary burning sensation. Other side effects
`include eye redness, discharge, watery eyes, eye pain, foreign body sensation,
`itching, stinging, and blurred vision. 
`
`You are encouraged to report negative side effects of prescription drugs to the
`FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
`
`Please click here http://www.allergan.com/assets/pdf/restasis-multidose_pi
`
`http://www.prnewswire.com/news-releases/allergan-introduces-restasis-multidose-cyclosporine-ophthalmic-emulsion-005-a-new-delivery-system-for-the-one-and-only-fda-app...
`
`

`

`Page 4 of 6
`
`About Allergan plc
`
`Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
`pharmaceutical company and a leader in a new industry model – Growth Pharma. 
`Allergan is focused on developing, manufacturing and commercializing branded
`pharmaceuticals, devices and biologic products for patients around the world.
`
`Allergan markets a portfolio of leading brands and best-in-class products for the
`central nervous system, eye care, medical aesthetics and dermatology,
`gastroenterology, women's health, urology and anti-infective therapeutic
`categories.
`
`Allergan is an industry leader in Open Science, the Company's R&D model, which
`defines our approach to identifying and developing game-changing ideas and
`innovation for better patient care.  This approach has led to Allergan building one
`of the broadest development pipelines in the pharmaceutical industry with 70+
`mid-to-late stage pipeline programs in development.
`
`Our Company's success is powered by our more than 16,000 global colleagues'
`commitment to being Bold for Life.  Together, we build bridges, power ideas, act
`fast and drive results for our customers and patients around the world by always
`doing what is right.
`
`With commercial operations in approximately 100 countries, Allergan is
`committed to working with physicians, healthcare providers and patients to deliver
`innovative and meaningful treatments that help people around the world live
`longer, healthier lives every day.
`
`For more information, visit Allergan's website at www.Allergan.com.
`
`http://www.prnewswire.com/news-releases/allergan-introduces-restasis-multidose-cyclosporine-ophthalmic-emulsion-005-a-new-delivery-system-for-the-one-and-only-fda-app...
`
`

`

`Page 5 of 6
`
`Forward-Looking Statement
`
`Statements contained in this press release that refer to future events or other non-
`historical facts are forward-looking statements that reflect Allergan's current
`perspective of existing trends and information as of the date of this release. Except
`as expressly required by law, Allergan disclaims any intent or obligation to update
`these forward-looking statements. Actual results may differ materially from
`Allergan's current expectations depending upon a number of factors affecting
`Allergan's business. These factors include, among others, the difficulty of predicting
`the timing or outcome of FDA approvals or actions, if any; the impact of
`competitive products and pricing; market acceptance of and continued demand
`for Allergan's products; difficulties or delays in manufacturing; and other risks and
`uncertainties detailed in Allergan's periodic public filings with the Securities and
`Exchange Commission, including but not limited to Allergan's Annual Report on
`Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form
`10-Q for the quarter ended June 30, 2016 (certain of such periodic public filings
`having been filed under the "Actavis plc" name). Except as expressly required by
`law, Allergan disclaims any intent or obligation to update these forward-looking
`statements.
`
`CONTACTS:      
`Investors:   
`Lisa DeFrancesco   
`(862) 261-7152
`
`Media:
`Mark Marmur   
`(973) 906-1526
`
`Fran DeSena  
`(973) 517-3132   
`
`http://www.prnewswire.com/news-releases/allergan-introduces-restasis-multidose-cyclosporine-ophthalmic-emulsion-005-a-new-delivery-system-for-the-one-and-only-fda-app...
`
`

`

`Page 6 of 6
`
`SOURCE Allergan plc
`
`Related Links
`http://www.allergan.com
`
`http://www.prnewswire.com/news-releases/allergan-introduces-restasis-multidose-cyclosporine-ophthalmic-emulsion-005-a-new-delivery-system-for-the-one-and-only-fda-app...
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket